Analysed TSCAN THERAPEUTICS INC (TCRX:NASDAQ) News Sources
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
25-03-2026
yahoo.com
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
08-04-2026
yahoo.com
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
27-04-2026
yahoo.com
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
06-05-2026
yahoo.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
03-06-2026
yahoo.com
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
22-06-2026
yahoo.com
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
24-06-2026
yahoo.com
What is the current price of TSCAN THERAPEUTICS INC (TCRX:NASDAQ)?
The current price of TSCAN THERAPEUTICS INC (TCRX:NASDAQ) is $0.7416.
TSCAN THERAPEUTICS INC (TCRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TSCAN THERAPEUTICS INC (TCRX:NASDAQ) since the previous trading day is $-0.0324.
TSCAN THERAPEUTICS INC (TCRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TSCAN THERAPEUTICS INC (TCRX:NASDAQ) since the previous trading day is -4.186%.
What is the most recent average sentiment score for TSCAN THERAPEUTICS INC (TCRX:NASDAQ)?
The most recent average sentiment score for TSCAN THERAPEUTICS INC (TCRX:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for TSCAN THERAPEUTICS INC (TCRX:NASDAQ)?
The most recent sentiment for TSCAN THERAPEUTICS INC (TCRX:NASDAQ) is .
SEC-8K** Filing Available For TSCAN THERAPEUTICS INC (TCRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.